How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,426 results for

Daily Energy Allowance

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

under the curve AUCinf area under the concentration-time curve from 0 to infinity AUClast area under the concentration –time curve from zero to time of last measurable concentration BCS biopharmaceutical classification system bid twice daily BMD bone mineral density BMI body mass index Broad pool pooled safety data from all seven ertugliflozin phase III studies BUN blood urea nitrogen CFU colony forming units CHMP Committee for Medicinal Products for Human use CI confidence interval cLDA constrained (...) /dissipation of the initial concentration DXA dual-energy x-ray absorptiometry E5 ertugliflozin 5 mg qd (Study P005/1019) E5/S100 ertugliflozin 5 mg qd + sitagliptin 100 mg qd (Study P005/1019) E15 ertugliflozin 15 mg qd (Study P005/1019) E15/S100 ertugliflozin 15 mg qd + sitagliptin 100 mg qd (Study P005/1019) ECHA European Chemicals Agency ECG Electrocardiogram eGFR estimated glomerular filtration rate ER approach excluding rescue treatment approach ERA Environmental risk assessment ertu ertugliflozin

2018 European Medicines Agency - EPARs

182. Home mechanical ventilation for patients with Amyotrophic Lateral Sclerosis: A CTS Clinical Practice Guideline

survival advantage with NIV compared to controls: 216 (range 94–681) days vs. 11 (1–283) days. There were six deaths of nine patients in the control group with better bulbar function within two weeks of enrollment. Five of the six had severe respiratory muscle weakness at enrollment. The “poor” bulbar function group showed improvement in health-related quality of life (HRQoL) if receiving NIV, but no survival benefit: 222 (range 75–1382) days vs 261 (6–878) days. The mean duration of daily use (...) HRQoL, 21,23,30–33 authors consistently reported improvements in HRQoL in cer- tain domains for patients using NIV. These included sustained improvements in mental health, energy/vitality, social isola- tion, fatigue and mastery. Physical function domains generally worsened as would be expected with disease progression. Gas exchange and pulmonary function All studies reporting gas exchange after initiation of NIV 31,32,34–36 show reduction of daytime partial pressure of carbondioxide(pCO2

2019 Canadian Thoracic Society

183. Our data-driven future in healthcare

of, their affiliated hospitals, universities, organisations or associations. Their participation should not be taken as endorsement by these bodies. The Academy is grateful to Understanding Patient Data for its ongoing support and input to this work. The Academy is also grateful for funding from a core grant from the Department for Business, Energy & Industrial Strategy to the Academy that was used to support this project. All web references were accessed in November 2018. This work is © the Academy of Medical (...) including provenance, accuracy, reliability and consistency over its life cycle. Data life cycle The different stages of the patient data journey. This involves various organisations and processes, including the generation and collection of data, curation, storage, access, use and its eventual destruction or legacy. Data processing The processing or curation of data to allow them to be used more effectively or linked with other datasets. Depersonalised data Data which have had any personal identifiers

2018 Academy of Medical Sciences

184. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

with a 17p deletion or TP53 mutation when chemo-immunotherapy is unsuitable. Adv Adverse erse reactions reactions The most common adverse reactions included diarrhoea, neutropenia, haemorrhage (for example, bruising), musculoskeletal pain, nausea, rash and pyrexia. For full details of adverse reactions and contraindications, see the summary of product characteristics. Recommended Recommended dose and dose and schedule schedule Ibrutinib is administered orally at a daily dose of 420 mg (3 tablets) until (...) from the company that it did not adjust for crossover in the 119 trial because this trial did not allow crossover to idelalisib. However, it heard from clinical experts that they considered it very likely that, after progression, patients leaving the trial would go on to receive other life-extending therapies, including ibrutinib, because of a compassionate-use programme for ibrutinib in place at the time. The company stated that this treatment switching was not within the trial period and so

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

185. Migalastat for treating Fabry disease

. Symptoms in adults include hearing impairment, skin rash, gastrointestinal problems and fatigue. For children, symptoms include low energy, fatigue, pain and gastrointestinal problems. The effects of the disease can disrupt daily activities and cause absences from work or school. Symptoms generally appear in childhood but usually go unrecognised until adulthood, when organ damage has already occurred. People with Fabry disease may need a carer relatively early in life; often this responsibility (...) were recruited to the open-label extension study from each arm of FACETS. One of the ERG's major concerns about the clinical evidence was the uncertainty in the comparability of migalastat and ERT. The pre-specified criteria for non-inferiority allowed a claim of comparability despite very wide confidence intervals for the outcome measures. The ERG was satisfied that the company's adverse event data did not raise any safety concerns over the use of migalastat. 4.20 The ERG noted a number

2017 National Institute for Health and Clinical Excellence - Highly specialised technology

186. Management of Alcohol-Related Liver Disease

important issue is the impact of alcohol drinking pat- terns, with controversy regarding the risks of binge drinking. In that respect, Askgaard found that daily drinking was associ- ated with the highest risk of liver cirrhosis, 16 whereas Aberg et al. found that binge drinking was associated with an increased risk of liver disease independently of average alcohol intake and confounders. 17 Further clinical and experimental studiesarerequiredtode?netheroleofALDandtheunderlying mechanisms. Importantly (...) alcohol? Never Monthly or less 2 to 4 times a month 2 to 3 times a week 4 or more times a week 2. How many drinks containing alcohol do you have on a typical day when you are drinking? 1 or 2 3 or 4 5 or 6 7 to 9 10 or more 3. How often do you have 5 or more drinks on one occasion? Never Less than monthly Monthly Weekly Daily or almost daily 4. How often during the last year you found that you were not able to stop drinking once you had started? Never Less than monthly Monthly Weekly Daily or almost

2018 European Association for the Study of the Liver

187. Management of hepatocellular carcinoma

, corona enhancement, presence of cap- sule, mosaic architecture, nodule-in-nodule architecture, intralesional haemorrhage. 170 Indeed, they increase the likeli- hood of a lesion being an HCC. However, they do not have a speci?city approaching 100% and therefore do not allow a con- clusive diagnosis of HCC. Comparison of CT vs. contrast-enhanced MRI using hepatobiliary contrast agents Multiple studies have compared the diagnostic performance of multiphasic CT with gadoxetic acid-enhanced MRI. 171–179 (...) lesions in cirrhosis. However, CEUS with pure blood pool contrast agents, such as those containing sul- fur hexa?uoride or octa?uoropropane with a phospholipid shell, utilised in Europe and North America for liver investiga- tions, is not a panoramic technique, because the arterial phase is too short to allow adequate exploration of the entire liver and deeply seated lesions may be dif?cult to visualise. Conse- quently, it was reported to miss around 13% of HCC visible on CT or MRI. 213 CEUS, can

2018 European Association for the Study of the Liver

188. Nutrition in Chronic Liver Disease

. (Grade II-2, C2) Optimal daily energy intake should not be lower than the recommended 35kcal/kg. actual BW/d (in non- obese individuals). (Grade II-2, B1) Optimal daily protein intake should not be lower than the recommended 1.2–1.5g/kg. actual BW/d. (Grade II-2, B1) Include late evening oral nutritional supplementation and breakfast in dietary regimen of malnourished decompensated cirrhotic patients. (Grade II-1, B1) BCAAsupplementsandleucineenrichedaminoacidsup- plements should be considered (...) practice in patients with neurologic coma, nutrition should be provided by nasogastric tube or parenterally. Recommendations Nutritional status and the presence of sarcopenia should be evaluated in patients with HE. (Grade II-3, B1) Avoid protein restriction in patients with HE. (Grade II-1, A1) Optimal daily protein and energy intake should not be lower than the general recommendations for cirrhotic patients (recommendations 14 and 15). (Grade II-1, A1) Encourage the consumptionof vegetables

2018 European Association for the Study of the Liver

189. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

about the effectiveness and harms of pharmacologic and nonpharmacologic treatments for exacerbations of chronic obstructive pulmonary disease (ECOPD). Data sources. Embase ® , Epub Ahead of Print, In-Process & Other Non-Indexed Citations, MEDLINE ® Daily, MEDLINE, Cochrane Central Registrar of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus from database inception to January 2, 2019. Review methods. We included randomized controlled trials (RCTs) that evaluated (...) , routes of administration, and duration of treatment) of antibiotics and corticosteroids. The majority of studies were conducted in hospitalized patients with moderate or severe ECOPD with only a small number of studies conducted in outpatients with mild or mild to moderate ECOPD. Lung function was the most frequently assessed outcome, and often studies did not measure final health outcomes, such as mortality, resolution of exacerbation, hospital readmission etc., to allow for assessment

2019 Effective Health Care Program (AHRQ)

190. Management of symptomatic hypermobility in children and young people

assessment will allow the OT to identify barriers to occupational performance and design the most appropriate intervention to maximise function. The main aim of OT intervention is to promote self- management where possible and this can be achieved through a variety of means. Assessment must be age and developmentally appropriate and tailored to the CYP’s individual needs. Activities of daily living Advice, education, strategies, functional goals, hand and shoulder exercise and small aids can improve CYP (...) ? Encouragement to maintain a healthy lifestyle, maintain hydration, eat a well- balanced diet, participate in regular gentle exercise, participate fully in school, activities and social events, and to get quality sleep are important ? Children and young people may benefit from joint protection advice and energy conservation principles for carrying out everyday tasks, to avoid placing unnecessary strain on their joints and minimising pain. Often encouragement is needed to include appropriate exercise

2019 British Society for Rheumatology

191. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms

of substances with diuretic properties) or pharmacological management are either inadequate or inappropriate, warranting consideration of one of the many invasive procedures available for the treatment of LUTS attributed to BPH. Indications for the use of one of these modalities may include a desire by the patient to avoid taking a daily medication, failure of medical therapy to sufficiently ameliorate bothersome LUTS, and certain conditions that require more aggressive intervention where medical therapy (...) making approach to reach a treatment choice, which may necessitate a referral to another clinician for the chosen treatment. In all instances, patients should be provided with the risk/benefit profile for all treatment options in light of their circumstances to allow them to make informed decisions regarding their treatment plans. GUIDELINE STATEMENTS EVALUATION AND PEROPERATIVE TESTING 1. Clinicians should take a medical history and utilize the AUA-Symptom Index (AUA-SI) and urinalysis

2019 American Urological Association

193. Incontinence after Prostate Treatment

and extended survivorship. Practitioners benefit from being able to assess which patient will likely expe- rience further symptom recovery versus those who will not. This allows clinicians to set clear and reason- able expectations regarding the short-, medium-, and long-term sequela of IPT. Although most clinicians are familiar with the more commonly known term “post-prostatectomy inconti- nence,” this guideline uses the term IPT, which is more inclusive given that it covers the management of patients who (...) clinicians for which there may or may not be evidence in the medical literature Expert Opinion A statement, achieved by consensus of the Panel, that is based on members clinical training, experience, knowledge, and judgment for which there is no evidence 8 AUA and SUFU as well as external content experts. Additionally, a call for reviewers was placed on the AUA website from January 14-28, 2019 to allow any additional interested parties to request a copy of the document for review. The guideline was also

2019 American Urological Association

194. Integrated care for older people (?ICOPE)?: guidance for person-centred assessment and pathways in primary care

its contents and by organizing the experts’ meetings. We also benefited from the inputs of participants at the annual meeting of WHO Clinical Consortium on Healthy Ageing, December 2018. The WHO Department Ageing and Life Course acknowledges the financial support of the Government of Japan, the Government of Germany and the Kanagawa Prefectural Government in Japan. Editing by Green Ink. ivABBREVIATIONS ADLs activities of daily living BMI body mass index CBT cognitive behavioural therapy ICOPE (...) , integrated approach also embraces the context of individuals’ daily lives, including the impact of their health and needs on those close to them and in their communities. There are ?ve steps to meeting older people’s health and social care needs with an integrated care approach, as shown in the following general pathway. ASSESSING OLDER PEOPLE’S NEEDS AND DEVELOPING A PERSONALIZED CARE PLAN KEY POINTS • The identi?cation of older people in the communi- ty with priority conditions associated with declines

2019 World Health Organisation Guidelines

195. Assessment and Management of Patients at Risk for Suicide

. However, there was no increase in the prevalence of suicide attempts between 2016 and 2017 for this age group. SAMHSA notes that this increase in suicide-related behavior over the past 10 years co-occurs with a similar increase in the prevalence of mental health VA/DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide May 2019 Page 8 of 142 conditions that cause significant impairment in daily life functioning, especially the occurrence of major depressive

2019 VA/DoD Clinical Practice Guidelines

196. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights

that there will need to be meaningful engagement of affected communities. UPDATING OF THE GUIDELINE The concept for the format of this guideline is a “living guideline”. In a fast-moving field, this approach will allow for continual review of new evidence to inform further versions of the “living” document. The recommendations presented in this publication represent a subset of prioritized self- care interventions for SRHR, and this guideline aims to gradually include a broader set of self-care interventions over

2019 World Health Organisation Guidelines

197. Management of Stroke Rehabilitation

patients, poor functional outcomes are commonplace. Approximately 44% of individuals aged 18-50 experience moderate disability after stroke, requiring at least some assistance with activities of daily living (ADL) and/or mobility (modified Rankin Scale score >2).[3] Even in patients with so-called “mild” or “improving” stroke, a recent study found that only 28% were discharged to home, 16% required admission to acute rehabilitation facilities, and 11% were admitted to skilled nursing facilities.[4] VA (...) and independence. Abbreviations: ADLs: activities of daily living; DoD: Department of Defense; VA: Department of Veterans Affairs C. Conflicts of Interest At the start of this guideline development process and at other key points throughout, the project team was required to submit disclosure statements to reveal any areas of potential conflict of interest (COI) in the past 24 months. Verbal affirmations of no COI were used as necessary during meetings throughout the guideline development process. The project

2019 VA/DoD Clinical Practice Guidelines

198. Management of Rheumatod Arthritis

in view of its association with high CV risk. Talk to a health care worker if you are experiencing symptoms of depression, having relationship problems or facing sleep difficulties. 45 Management of Rheumatoid Arthritis APPENDIX 5 PRINCIPLES OF JOINT PROTECTION The purpose of joint protection is to allow patients to participate in daily activities with the least amount of damage to the affected joints. These principles can help to reduce pain, inflammation and injury caused by excessive stress (...) and experts in the field contacted to identify relevant studies. All searches were conducted from 29 May 2017 to 2 June 2017. Literature search was repeated for all clinical questions at the end of the CPG development process allowing any relevant papers published before 31 January 2019 to be included. Future CPG updates will consider evidence published after this cut-off date. The details of the search strategy can be obtained upon request from the CPG Secretariat. Reference was also made to other

2019 Ministry of Health, Malaysia

199. Management of Heart Failure (4th Edition)

voltage, evidence of ischaemia, LV hypertrophy and arrhythmias. Chest radiograph - To look for pulmonary congestion, cardiomegaly and presence of underlying lung pathology. - Patients with HFpEF may have a normal cardiac size. Blood tests FBC, renal function, liver function, serum glucose, lipid profile Urinalysis To look for proteinuria, glycosuria. OTHER IMPORTANT INVESTIGATIONS Echocardiography This will allow assessment of: ? LV chamber size, volume and systolic function ? LV wall thickness

2019 Ministry of Health, Malaysia

200. Physical activity evidence review technical report

for the valuable contribution that physically active 33 Study details Results of the review Main findings and evidence grading Included study types: Controlled intervention studies. Of the 10 studies reporting physical activity outcomes for physically active academic lesson interventions on daily physical activity levels, eight reported statistically significant increase in physical activity outcomes, and two reported no significant change. Three were found to exceed Cohen’s convention for a large effect (one (...) ) The intervention group also increased moderate intensity physical activity (MD 40 minutes per week, 95% C.I. 29 to 52 minutes per week). This study allowed participants to self-select the type of physical activity they undertook. Intervention: Community-based interventions in older adults living in rural and regional settings. Evidence statement C: There is some evidence supporting this intervention to promote physical activity, but it is not conclusive. Author’s conclusions: There is limited rigorous research

2019 Public Health Wales Observatory Evidence Service

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>